Table 1. Patient baseline demographics and disease characteristics.
Data are n (%) unless otherwise stated. HCV GT1 subtype (Coalesce) is based on the NS5B assay, and if not available on LIPA HCV II or Trugene results.
| 12-week group (n = 123) | >12-week group (n = 40) | Overall (N = 163) | |
|---|---|---|---|
| Male | 65 (53) | 28 (70) | 93 (57) |
| Race | |||
| White | 98/107 (92) | 32/33 (97) | 130/140 (93) |
| Age, years, median (min, max) | 47 (23, 68) | 50 (26, 64) | 47 (23, 68) |
| Body mass index, kg/m2, median (range) | 25 (17–39) | 25 (16–34) | 25 (16–39) |
| HCV GT1 subtype | |||
| 1a | 49 (40) | 18 (45) | 67 (41) |
| With Q80K* | 6/47 (13) | 5/18 (28) | 11/65 (17) |
| 1b | 74 (60) | 22 (55) | 96 (59) |
| Baseline HCV RNA | |||
| ≤800,000 IU/mL | 33 (27) | 3 (8) | 36 (22) |
| METAVIR fibrosis score+ | |||
| F0–1 | 93 (76) | 25 (63) | 118 (72) |
| F2 | 29 (24) | 15 (38) | 44 (27) |
| Missing | 1 (1) | 0 | 1 (1) |
| IL28B genotype | |||
| CC | 32 (26) | 8 (20) | 40 (25) |
| CT | 73 (59) | 20 (50) | 93 (57) |
| TT | 18 (15) | 12 (30) | 30 (18) |
*Q80K data unavailable for two patients with GT1a in the 12-week group
+Patients were assessed with invasive (liver biopsy; (n = 34)) and/or non-invasive assessment of fibrosis (transient elastography; n = 128), with the worst assessment being used for stage of fibrosis. SD: standard deviation.